CLLS compared with NRXP: revenue, margins and what each company keeps, and the suppliers and customers both name

CLLSCellectis S.A.

Mkt capRevenueRevenue

NRXPNRX Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

CLLSCellectis S.A.

NRXPNRX Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only CLLS 4

TMOLife Technologiessupplier

ALLOAllogene Therapeuticscustomer

AZNAstraZeneca AB (AZ Ireland)customer

—Servierunlistedcustomer

Shared 0

No shared counterparties.

Only NRXP 3

—Nephron Pharmaceuticalsunlistedsupplier

—Emobotunlistedsupplier

—Relief Therapeuticsunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

CLLSCellectis S.A.

1.03▼−12.24%· post 1.03

Mkt cap$103.3MRevenue—

NRXPNRX Pharmaceuticals, Inc.

2.29▼−8.03%· post 2.26

ClosedNov 5 '26

Mkt cap$107.8MRevenue$6,000Q2 FY26

Compare

ClosedNov 5 '26

CLLSCellectis S.A.

NRXPNRX Pharmaceuticals, Inc.

1.03▼−12.24%post 1.03

Price

2.29▼−8.03%post 2.26

$103.3M

Mkt cap

$107.8M

—

Revenue

$6,000Q2 FY26

CLLS1.03▼−12.24%vsNRXP2.29▼−8.03%ClosedNov 5 '26